Brighton Jones LLC’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Brighton Jones LLC’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-791	Closed	-$8K	–	325
2019 Q2	$8K	Hold	791	–	–	﹤0.01%	307
2019 Q1	$21K	Hold	791	–	–	﹤0.01%	304
2018 Q4	$18K	Hold	791	–	–	﹤0.01%	258
2018 Q3	$44K	Hold	791	–	–	0.01%	279
2018 Q2	$57K	Hold	791	–	–	0.01%	296
2018 Q1	$49K	Hold	791	–	–	0.01%	287
2017 Q4	$100K	Hold	791	–	–	0.01%	287
2017 Q3	$108K	Buy	+791	New	+$106K	0.01%	286

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Brighton Jones LLC's TTPH Position: Q3 2019 in Review

Brighton Jones LLC sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 791 shares — an estimated $8K sold.

Brighton Jones LLC first reported a position in TTPH in Q3 2017 and held it in 8 quarters. The position peaked at $108K in Q3 2017. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

Brighton Jones LLC reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Brighton Jones LLC sold 791 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $8K.
Brighton Jones LLC first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
Brighton Jones LLC's Tetraphase Pharmaceuticals, Inc. position peaked at $108K in Q3 2017.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Brighton Jones LLC's 13F filing for Q3 2019, filed 28 Oct 2019.